CN108379215B - Lyophilized powder composition with skin whitening effect and cosmetic composition containing same - Google Patents
Lyophilized powder composition with skin whitening effect and cosmetic composition containing same Download PDFInfo
- Publication number
- CN108379215B CN108379215B CN201810286740.4A CN201810286740A CN108379215B CN 108379215 B CN108379215 B CN 108379215B CN 201810286740 A CN201810286740 A CN 201810286740A CN 108379215 B CN108379215 B CN 108379215B
- Authority
- CN
- China
- Prior art keywords
- powder composition
- lyophilized powder
- skin
- nicotinamide
- trehalose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a freeze-dried powder composition with a skin whitening effect, which is characterized by comprising 75-95% of stem cell factor supernatant, 2-10% of trehalose, 5-15% of mannitol and 1-5% of nicotinamide by mass percent, and can improve the activity of cells and maintain the normal physiological metabolism of skin, so that the safe and effective skin whitening effect is achieved.
Description
Technical Field
The invention relates to the field of cosmetics, in particular to a freeze-dried powder composition with a skin whitening effect and a cosmetic composition using the freeze-dried powder composition.
Background
At present, the principle of the formula of the cosmetics with the skin whitening effect is mainly focused on inhibiting the activity of the tyrosinase, and various natural sources of the tyrosinase inhibitors, such as kojic acid, arbutin, liquorice extract, tricholoma matsutake extract and the like, have been reported in the literature, and have proved to have good clinical effects. With the development of biotechnology, research in the stem cell field is continuously widened and deepened, and during the culture process of the stem cells, the growth and proliferation of the cells are regulated and controlled by paracrine function synthesis and secretion of various bioactive components such as cell growth factors and the like, so that the vitality of damaged cells is improved. However, the current skin care products using stem cell growth factors are not many, and for technical reasons, the skin care products for researching stem cell growth factors are few.
Disclosure of Invention
In order to solve the above problems, the invention provides a cosmetic lyophilized powder composition with skin whitening effect, which can improve the activity of cells and maintain the normal physiological metabolism of skin, thereby achieving the safe and effective skin whitening effect.
The invention provides a freeze-dried powder composition with skin whitening effect, which is characterized by comprising 75-95% of stem cell factor supernatant, 2-10% of trehalose, 5-15% of mannitol and 1-5% of nicotinamide by mass percent.
Furthermore, the freeze-dried powder composition also comprises 0.1-3% of tranexamic acid and 0.01-3% of vitamin C derivatives.
Further, the freeze-dried powder composition comprises 80-90% of stem cell factor supernatant, 3-8% of trehalose, 7-12% of mannitol and 1-3% of nicotinamide.
Furthermore, the freeze-dried powder composition also comprises 0.1-2% of tranexamic acid and 0.01-2% of vitamin C derivatives.
Further, the freeze-dried powder composition comprises the following components in percentage by mass
Stem cell factor supernatant: 81.2%, trehalose: 5%, mannitol: 12%, nicotinamide: 1%, tranexamic acid: 0.3%, vitamin C derivative: 0.5 percent.
Further, the freeze-dried powder composition comprises the following components in percentage by mass: 82.3%, trehalose: 5%, mannitol: 10%, nicotinamide: 2%, tranexamic acid: 0.2%, vitamin C derivative: 0.5 percent.
Further, the lyophilized powder composition of any one of claims 1-6 and a solvent for dissolving the lyophilized powder composition, wherein the solvent comprises 0.0001-0.001% of sodium hyaluronate and more than 99% of water in percentage by mass.
Further, the ratio of the freeze-dried powder composition to the solvent is 1: 2.
the invention adopts the stem cell growth factor which can make the skin white, and the stem cell growth factor has homology with the human body, higher absorptivity and better skin affinity. Through compounding with nicotinamide (vitamin B3) or tranexamic acid (tranexamic acid), the generation and transfer of melanin are inhibited in a combined and synergistic mode, the activity of cells is improved, and the normal physiological metabolism of skin is maintained, so that the safe and effective whitening effect is achieved.
Drawings
FIG. 1 is a differential analysis of the effect of the lyophilized powder composition of example 1 on melanin at the target site on the left face of a test subject;
FIG. 2 is a differential analysis of the effect of lyophilized powder composition of example 2 on melanin in the target site of the left face of a test subject.
Detailed Description
The following will describe in detail embodiments of the lyophilized powder composition of the present invention. It should be noted that the present invention is not limited by the following examples.
The composition of the invention takes the supernatant of the stem cell factor as the main component, is assisted by vitamin C or derivatives thereof, vitamin B3 and tranexamic acid, forms a freeze-dried powder composition by low-temperature vacuum, and forms a cosmetic composition by taking water and sodium hyaluronate as solvents.
In the components for preparing the cosmetic freeze-dried powder composition, the supernatant of the stem cell factor is cell culture supernatant collected in the passage amplification culture process of clinical umbilical cord mesenchymal stem cells, contains various cell growth factors with biological activity, and the cell factors have the effects of promoting metabolism, proliferation and growth of fibroblasts and epidermal cells. According to the invention, the supernatant of the stem cell factor is 75-95% by mass, preferably 80-90% by mass, so that the stem cell factor can repair aged collagen fibers and elastic fibers by promoting the proliferation of fibroblasts in a dermis layer, more synthesize and secrete macromolecules such as collagen, hyaluronic acid and the like, improve skin microcirculation, provide a good nutrition environment, maintain a certain amount of skin fat, reduce skin elasticity, make the skin uniform and compact and reduce wrinkles. The stem cell factor is mainly absorbed by the penetration of the hair follicle wall, sweat glands and sebaceous glands, specifically binds to cell surface receptors to play a biological role, further regulates the functions of skin cells and endows the cells with new activity, thereby solving the problems of beauty and skin care at the cellular and molecular level.
In addition, vitamin C is a safe and effective skin whitening agent, has the effects of promoting the synthesis of ossein and inhibiting the peroxidation of lipid compounds, and contains 0.01-3% of vitamin C derivatives, preferably 0.01-2%, so that the generation of melanin can be inhibited, and the dark skin can be restored to be tender and white; meanwhile, lipid peroxidation and aging are inhibited, free radicals are resisted, free radical damage caused by ultraviolet rays can be delayed, the free radicals can be neutralized, and the skin blackening prevention effect is facilitated.
In addition, the invention also contains nicotinamide, also known as vitamin B3, which can promote energy metabolism of cells, is a component required by lipid metabolism, oxidation of tissue respiration and glycogen decomposition, and can affect normal respiration and metabolism of cells when the component is deficient, thus causing pellagra. The invention contains 1 to 5 percent of nicotinamide, preferably 1 to 3 percent of nicotinamide, which can act on the produced melanin and reduce the transfer of the melanin to surface layer cells; accelerating metabolism and promoting the exfoliation of melanocyte containing keratinocyte; promoting the synthesis of epidermal protein and improving skin texture.
In addition, the invention also contains tranexamic acid (tranexamic acid), which is an artificially synthesized amino acid, can inhibit the catalytic action of protease on the hydrolysis of peptide bonds, can directly block the activation of melanocytes and improve the active state of black spot activated factor groups. The present invention contains 0.1% to 3%, preferably 0.1% to 2% of tranexamic acid, which can prevent and improve pigmentation of the skin, completely block the pathway of melanin generation due to ultraviolet irradiation, and thus can effectively prevent and improve pigmentation of the skin.
In addition, the freeze-dried powder composition also comprises trehalose and mannitol. The trehalose has the excellent characteristics of keeping cell activity and biomacromolecule activity, can effectively protect an epidermal cell membrane structure, activate cells, condition skin and enable the skin to be healthy, natural and elastic; mannitol is a moisturizing ingredient and can effectively contain epidermal cell membranes, so that the skin is full of vitality. The skin care product contains 2-10% of trehalose, 5-15% of mannitol, preferably 3-8% of trehalose and 7-12% of mannitol, and by the proportion, the skin can be effectively conditioned, skin microcirculation is improved, and a good nutritional environment is provided.
The specific use of the components of the present invention will be described in detail below.
Example 1
The components for forming the freeze-dried powder composition and the mass percentage content are as follows:
stem cell factor supernatant 81.20%
Trehalose 5.00%
12.00 percent of mannitol
Nicotinamide 1.00%
0.30 percent of tranexamic acid
Vitamin C derivatives: 0.50 percent
The solvent comprises the following components in percentage by weight:
99.999 to 99.9999 percent of water
Sodium hyaluronate: 0.0001 to 0.001 percent
Wherein the water is cosmetic deionized water or purified water or distilled water.
Example 2
The components for forming the freeze-dried powder composition and the mass percentage content are as follows:
stem cell factor supernatant 82.30%
Trehalose 5.00%
10.00 percent of mannitol
2.00 percent of nicotinamide
0.20 percent of tranexamic acid
Vitamin C derivative 0.50%
The solvent comprises the following components in percentage by weight:
99.999 to 99.9999 percent of water
Sodium hyaluronate: 0.0001 to 0.001 percent
Wherein the water is cosmetic deionized water or purified water or distilled water.
The preparation method of the freeze-dried powder combination product comprises the following steps:
1. uniformly mixing the supernatant of the stem cell factor, trehalose, mannitol, nicotinamide, tranexamic acid and vitamin C derivatives according to a proportion, and subpackaging by using ampoules according to the specification of 1 ml/bottle;
2. placing the mixture in a freeze-drying device, freeze-drying the mixture for 24-36 hours under the conditions that the pressure is 50-100 Pa and the temperature is-30-35 ℃, and preferably covering and sealing the mixture to obtain the cosmetic freeze-dried powder with the skin whitening effect;
3. stirring and dissolving sodium hyaluronate in water according to a proportion, subpackaging by ampoule according to the specification of 2 ml/bottle, capping and sealing to obtain a solvent;
4. dissolving 1 part of the lyophilized powder in 1 part of solvent to obtain cosmetic.
< effects of the invention >
The two groups of cosmetic compositions are subjected to skin whitening efficacy tests in crowds, and the skin color improvement condition of a user in the using process is observed. The cosmetic composition prepared in example 1 was applied to 35 healthy women using a part of the left side face as a target site according to a predetermined application method, and the skin melanin analysis was performed on the subjects at 0 day, the second week, and the fourth week.
Volunteer information
It should be noted that the content of melanin is an important factor for determining the skin color of a human body, and the skin color becomes darker as the content of melanin is higher. The melanin of the facial skin is measured by a Mexameter MX18, and the smaller the value of the melanin, the lower the melanin content, and the better the whitening effect of the product. Data were counted using SPSS 11.5For Windows software.
< effects of example 1 >
After the product of the invention example 1 is used, the melanin content of the skin at the target part of the left face is obviously reduced, and compared with D0, the melanin content is respectively reduced by 5.56% and 11.11% when D14 and D28 are revisited; the analysis of the difference of the prescriptions revealed that there was a significant difference in melanin content (P <0.001) between the revisit at D14 and D28 compared to D0 (as shown in table 1, fig. 1).
TABLE 1 differential analysis of melanin in the skin of the left face after use of the test products
From the above data, it can be seen that the pigment index is decreased from the basic value in both the second and fourth weeks, and that the whitening effect is shown already in the second week and continues with the lapse of time.
< effects of example 2 >
After the product of the invention in the example 2 is used, the melanin content of the skin at the target part of the left face is obviously reduced, and compared with D0, the melanin content is respectively reduced by 6.53 percent and 11.43 percent when the product is revisited by D14 and D28; the analysis of the difference of the formulas revealed that there was a significant difference in melanin content (P <0.001) between the revisit at D14 and D28 compared to D0 (as shown in table 2, fig. 2).
TABLE 2 differential analysis of melanin in the skin of the left face after use of the test products
From the above data, it can be seen that the pigment index is decreased from the basic value in both the second and fourth weeks, and that the whitening effect is shown already in the second week and continues with the lapse of time.
In conclusion, the cosmetic composition disclosed by the invention can effectively inhibit the generation and transfer of melanin, improve the activity of cells and maintain the normal physiological metabolism of skin, thereby achieving the effects of safety and effective whitening. In addition, the cosmetic composition is prepared by combining freeze-dried powder and a solvent, and can effectively maintain the biological activity of the stem cell factor by applying a low-temperature vacuum freeze-drying technology, and meanwhile, no preservative is added, so that the irritation of the preservative to the skin is avoided.
The embodiments described in this specification are merely illustrative of implementations of the inventive concept and the scope of the present invention should not be considered limited to the specific forms set forth in the embodiments but rather by the equivalents thereof as may occur to those skilled in the art upon consideration of the present inventive concept.
Claims (6)
1. The freeze-dried powder composition with the skin whitening effect is characterized by comprising the following components in percentage by mass: 75-95% of stem cell factor supernatant, 2-10% of trehalose, 5-15% of mannitol, 1-5% of nicotinamide, 0.1-3% of tranexamic acid and 0.01-3% of vitamin C;
the stem cell factor supernatant is cell culture supernatant collected during passage amplification culture of clinical-grade umbilical cord mesenchymal stem cells.
2. The lyophilized powder composition of claim 1, wherein the lyophilized powder composition comprises: 80-90% of stem cell factor supernatant, 3-8% of trehalose, 7-12% of mannitol, 1-3% of nicotinamide, 0.1-2% of tranexamic acid and 0.01-2% of vitamin C.
3. The lyophilized powder composition of claim 1, comprising, in mass percent: 81.2%, trehalose: 5%, mannitol: 12%, nicotinamide: 1%, tranexamic acid: 0.3%, vitamin C: 0.5 percent.
4. The lyophilized powder composition of claim 1, comprising, in mass percent: 82.3%, trehalose: 5%, mannitol: 10%, nicotinamide: 2%, tranexamic acid: 0.2%, vitamin C: 0.5 percent.
5. A cosmetic composition, comprising the lyophilized powder composition according to any one of claims 1 to 4, and a solvent for dissolving the lyophilized powder composition, wherein the solvent comprises 0.0001% to 0.001% by mass of sodium hyaluronate and 99% or more by mass of water.
6. The cosmetic composition of claim 5, wherein the ratio of the lyophilized powder composition to the vehicle is 1: 2 by volume percentage.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810286740.4A CN108379215B (en) | 2018-03-30 | 2018-03-30 | Lyophilized powder composition with skin whitening effect and cosmetic composition containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810286740.4A CN108379215B (en) | 2018-03-30 | 2018-03-30 | Lyophilized powder composition with skin whitening effect and cosmetic composition containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108379215A CN108379215A (en) | 2018-08-10 |
CN108379215B true CN108379215B (en) | 2020-01-10 |
Family
ID=63073111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810286740.4A Active CN108379215B (en) | 2018-03-30 | 2018-03-30 | Lyophilized powder composition with skin whitening effect and cosmetic composition containing same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108379215B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020007563A1 (en) * | 2018-07-03 | 2020-01-09 | Unilever N.V. | Skin care kit |
CN110354003B (en) * | 2019-07-08 | 2022-05-27 | 广州贝研生物科技有限公司 | Application of tranexamic acid as freeze-dried powder excipient and freeze-drying process |
CN110227038B (en) * | 2019-07-08 | 2022-03-08 | 珠海贝美生物科技有限公司 | Freeze-dried powder with whitening activity and preparation method and application thereof |
CN113520960A (en) * | 2020-04-17 | 2021-10-22 | 常州伟博海泰生物科技有限公司 | Skin whitening and brightening lyophilized preparation, skin whitening and brightening lyophilized essence and preparation method thereof |
CN112957264A (en) * | 2021-02-26 | 2021-06-15 | 晟薇药业(上海)有限公司 | Freeze-dried powder based on beta-glucan as excipient and freeze-drying process thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105726387A (en) * | 2016-02-17 | 2016-07-06 | 佛山市芊茹化妆品有限公司 | Skin whitening microemulsion |
CN105708722A (en) * | 2016-03-15 | 2016-06-29 | 深圳市真兴病毒技术有限公司 | Factor composition and composite freeze-dried powder for promoting skin cell growth and skin care product |
CN106367389A (en) * | 2016-11-15 | 2017-02-01 | 东莞自然衡健康科技有限公司 | Preparation method and application of human umbilical cord mesenchymal stem cell factors |
-
2018
- 2018-03-30 CN CN201810286740.4A patent/CN108379215B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN108379215A (en) | 2018-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108379215B (en) | Lyophilized powder composition with skin whitening effect and cosmetic composition containing same | |
CN111000748A (en) | Polypeptide repairing cream and preparation method thereof | |
CN112656713A (en) | Cosmetic composition containing hyaluronic acid and/or derivatives thereof, and preparation method and application thereof | |
KR102006952B1 (en) | Cosmetics compositions for prevention and improvement of wrinkle | |
CN109330954B (en) | Whitening skin brightening lotion, preparation method thereof and tyrosinase inhibitor | |
CN113576975A (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
CN110585111A (en) | Anti-aging cosmetic additive and preparation method thereof | |
KR101810226B1 (en) | Cosmetic compositon containing complex extracts from salmon | |
EP4153125A1 (en) | Skin care product with protein matrix | |
CN114796024B (en) | Bionic sebum composition for skin barrier repair, and preparation method and application thereof | |
CN107648066A (en) | A kind of anti-aging skin-active shin moisturizer containing growth factor and preparation method thereof | |
CN110960480A (en) | Freckle-removing essence containing umbilical cord extract and preparation method thereof | |
KR101491463B1 (en) | Cosmetic composition for skin whitener containing fermented extract of green plum and method thereof | |
KR102382002B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex and natural ingredients | |
CN114831915B (en) | Moisturizing and repairing eye cream and preparation method thereof | |
JP2006241102A (en) | Scf isolation inhibitor and external composition for skin | |
KR102281606B1 (en) | A multifunctional cosmetic composition for elasticity, anti-wrinkle, inhibiting tyrosinase comprising peptide complex | |
CN113876626B (en) | Composition with protective effect on blue light induced skin cell damage and application of composition in cosmetics | |
CN116407486A (en) | Active composition, cosmetic composition, application of active composition, repairing essence and preparation method of repairing essence | |
US9040097B2 (en) | Compositions for improving skin appearance | |
KR101154772B1 (en) | Cosmetic composition containing the zizyphus jujuba fruit extract and walnut extract for moisturizing effect on the skin | |
CN113662876A (en) | Polypeptide beautifying essence and preparation method thereof | |
US20080305193A1 (en) | Cosmetic compositions | |
KR20160017891A (en) | Composition for protecting skin with antioxidant activity comprising egf and placenta | |
CN116115540B (en) | Skin anti-aging composition, application and daily chemical product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |